908 Devices

908 Devices, Inc. engages in the development of measurement devices for chemical and biochemical analysis. It offers products using mass spectrometry technology, an analytical technique for measuring the mass of charged molecules that is used in chemical analysis laboratories for applications, such as safety and security, food science, biotechnology, clinical diagnostics, and controlling industrial processes. Its products include desktops and handhelds. The company was founded by Kevin J. Knopp, Miller Scott, Steve Araiza, Andrew Bartfay, Michael Jobin, Christopher D. Brown, and Christopher J. Petty in 2012 and is headquartered in Boston, MA.

Earnings data Q1 2024

908 Devices reports strong Q1 revenue growth and international expansion

908 Devices reported strong revenue growth and recurring revenue, with a focus on expanding international presence. The company is addressing challenges in the bioprocessing environment and driving adoption of new products. They are uniquely positioned to capture opportunities in the forensics market and internationally.

908 Devices reports 9% revenue growth in Q2 2023

908 Devices demonstrated revenue growth and success in the forensics market, but faces challenges in the bioprocessing market and cost management. The company aims to capitalize on opportunities for revenue growth through new product launches and geographic expansion.

908 Devices reports mixed Q3 results, eyes MAVERICK sales in 2024

908 Devices reported mixed Q3 results with revenue growth but a decrease in recurring revenues. The company is focused on accelerating mass spec-based workflows, addressing proteomics and metabolomics opportunities, and building a compelling set of complementary technologies and devices for the PAT space. Despite challenges, they anticipate an exciting 2024 with a lessening macro and expanded desktop portfolio.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will report financial results for the first quarter 2024 before market open on Tuesday, April 30, 2024. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.908device.

908 Devices to Report First Quarter 2024 Financial Results on April 30, 2024

Thermo Fisher Scientific, Danaher Corporation, and Agilent Technologies are leading companies in the life science tools industry. Despite a long history of success with those firms, I believe long-term investors should diversify into growth opportunities that underlie the industry. 908 Devices, Inc. is a promising company focused on first-in-class mass spectrometry and bioprocess analysis tools, with a profitable future in store.

908 Devices: Rare Early-Stage Bioprocess Investment Opportunity

Bitdeer Technologies Group

NVIDIA

Robinhood revolutionized commission free investing, and it continues to do so today.

3 Stocks Under $10 That Wall Street Sees More Than 100% Upside This Year

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, announces the latest in international adoption of the MX908 for trace detection and identification of priority drugs and chemical threats. DrugDetect EU and NATO Support and Procurement Agency (NSPA) have both entered into new contracts to deploy the MX908, a handheld high-pressure mass spectrometry (HPMS) device. The MX908 will be used in a va.

908 Devices Trace Chemical Identification Technology Adopted by European Agencies

908 Devices Inc. (NASDAQ:MASS ) Q4 2023 Earnings Conference Call March 5, 2024 8:00 AM ET Company Participants Kelly Gura - IR Kevin Knopp - Co-Founder, CEO, President & Director Joseph Griffith - CFO & Treasurer Conference Call Participants Puneet Souda - Leerink Partners Daniel Arias - Stifel Jacob Johnson - Stephens Matthew Larew - William Blair Operator Hello, everyone, and welcome to the 908 Devices Fourth Quarter 2023 Financial Results Conference Call. My name is Seb and I will be the operator for your call today.

908 Devices Inc. (MASS) Q4 2023 Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today reported financial results for the quarter and full year ended December 31, 2023. "We made solid progress in 2023 towards our objectives. We have continued to see sustained growth of our handheld devices servicing customers in their efforts to combat the ongoing crisis of counterfeit drugs and opioids. For the full year we saw 28% growth.

908 Devices Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Revenue Outlook

BOSTON & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #bioprocessing--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, and Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and commercial-scale cell therapy manufacturing, announce a development collaboration to integrate in-line monitoring of key cell culture parameters into Cellares' Cell Shuttle system, a fully integrated, scal.

908 Devices and Cellares Collaborate to Integrate In-line Monitoring of Bioprocess Parameters into the Cell Shuttle, Cellares' Fully Integrated Cell Therapy Manufacturing Platform

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today announced it will participate in the following investor conferences. Cowen 44th Annual Healthcare Conference, Boston, MA Fireside chat on Wednesday, March 6th at 9:50 a.m. Eastern Time / 6:50 a.m. Pacific Time KeyBanc Life Sciences & MedTech Forum (Virtual) Fireside chat on Wednesday, March 20th at 3:45 p.m. Eastern Time / 12:45 p.m.

908 Devices to Participate in Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will report financial results for the fourth quarter and full year 2023 before market open on Tuesday, March 5, 2024. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time. Live audio of the webcast will be available on the “Investors” section of the company website at:.

908 Devices to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024

908 Devices Inc. (MASS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

908 Devices Inc. (MASS) Upgraded to Buy: What Does It Mean for the Stock?

Beam Therapeutics

Cathie Wood's Ark Invest has been at the center of the thematic investing revolution. Two of Wood's healthcare picks, 908 Devices and Beam Therapeutics, have garnered lofty price targets from analysts.

2 Cathie Wood Stocks That Could Soar in 2024, According to Wall Street

The consensus price target hints at a 100.4% upside potential for 908 Devices Inc. (MASS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in 908 Devices Inc. (MASS)? Wall Street Analysts Think 100.39%

BridgeBio Pharma Inc

Herbalife

For most of the year, the Russell 2000 has lagged far behind its peers, the S&P500 and the Nasdaq. However, the small-to-mid cap index appears to be closing the gap.

3 Russell 2000 Stocks That Are About to Get Absolutely Crushed

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today announced that it has expanded access to its leading trace detection technology in its handheld MX908 device through the addition of a weatherproof, digital communications port, thereby enabling companies to integrate the device into their systems to enhance the safety of their users and the public. The recent work with RADēCO, Inc., a ma.

908 Devices Announces MX908 Integration Capabilities

908 Devices Inc. (NASDAQ:MASS ) Q3 2023 Earnings Call Transcript November 7, 2023 8:30 AM ET Company Participants Kelly Gura - IR Kevin Knopp - Co-Founder, CEO, President & Director Joseph Griffith - CFO & Treasurer Conference Call Participants Steven Mah - TD Cowen Matthew Larew - William Blair Jacob Johnson - Stephens Daniel Arias - Stifel Operator Hello and welcome to today's 908 Devices Third Quarter 2023 Financial Results Conference Call. My name is Jordan and I'll be coordinating your call today.

908 Devices Inc. (MASS) Q3 2023 Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today reported financial results for the quarter ended September 30, 2023. "We are pleased with the step-up in our revenues from the second quarter and the positive growth trend over the past nine months, despite the challenging environment in the life sciences instrumentation and bioprocessing markets," said Kevin J. Knopp, CEO and Co-founder.

908 Devices Reports Third Quarter 2023 Financial Results and Narrows 2023 Revenue Outlook

BOSTON & LAKEWOOD, Colo.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, and medical technology company Terumo Blood and Cell Technologies (Terumo BCT) announce a collaboration to enable on-line monitoring of critical process parameters in Terumo BCT's Quantum Flex Cell Expansion System. The combination of the companies' automation technologies will help advance the development of life-saving cell.

908 Devices and Terumo Blood and Cell Technologies Collaborate to Add On-line Analytics to Quantum Flex Cell Expansion System

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, announces today that it has been awarded a total of $10.4 million in purchase orders from the United States Air Force and Air National Guard Fire & Emergency Services Program for its MX908 handheld mass spectrometry device with Aero module. Approximately a third of the orders include Aero module upgrades, training, and support for existing.

908 Devices Awarded $10.4M Order from the United States Air Force for its Handheld MX908 Device

BOSTON--(BUSINESS WIRE)--908 Devices Inc., (Nasdaq: MASS) a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will report financial results for the third quarter 2023 before market open on Tuesday, November 7, 2023. Company management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.908devi.

908 Devices to Report Third Quarter Financial Results on November 7, 2023

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, announces that it has entered the initial production phase of the Aerosol and Vapor Chemical Agent Detector (AVCAD) program. The company and its partner on the project, Smiths Detection, will initially produce 122 systems in this next phase. The systems, which have been in development and testing since 2019, are a next generation chemical detec.

908 Devices Enters Initial Production Phase of US Department of Defense Aerosol and Vapor Chemical Agent Detector Program

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, announces the launch of MAVERICK, an optical in-line analyzer that provides real-time monitoring and control of glucose, lactate, and total biomass in mammalian cell cultures, in addition to rich process fingerprint data to support large-scale efforts in predictive bioprocess modeling. MAVERICK is the first turn-key device to utilize Raman spec.

908 Devices Launches MAVERICK for Real-Time In-Line Monitoring of Multiple Bioprocess Parameters

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today announced it will participate in the upcoming Gilmartin Group Emerging Growth Company Showcase. 908 Devices' management is scheduled to present on Thursday, September 21 at 9:00 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.908devi.

908 Devices to Participate in the Gilmartin Group Emerging Growth Company Showcase

908 Devices announced Q2 FY23 results with an 8.9% increase in revenue, driven by a 27% increase in MX908 device sales. The company experienced a significant drop in gross profit margin and an increase in operating expenses, resulting in a higher net loss compared to Q2 FY22. The stock is trading 83% below its IPO price level and shows bearish price action, making it advisable to avoid investing in the company for now.

908 Devices: Not Worth Investing

COMPASS Pathways

Cathie Wood is an icon in the world of disruptive tech. Her firm ARK Invest holds positions in Beam Therapeutics, COMPASS Pathways, and 908 Devices.

3 Cathie Wood Stocks With Parabolic Growth Potential, According to Wall Street

Adaptive Biotechnologies

Cerus

Holley

Lucid Group

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

News for 908 Devices Stock (MASS)